Anika Therapeutics Inc. (NASDAQ:ANIK) is set to post its quarterly earnings results after the market closes on Tuesday, July 25th. Analysts expect Anika Therapeutics to post earnings of $0.44 per share for the quarter.
Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, May 3rd. The biotechnology company reported $0.37 EPS for the quarter, missing the Zacks’ consensus estimate of $0.38 by $0.01. The business had revenue of $23.39 million for the quarter, compared to the consensus estimate of $23.89 million. Anika Therapeutics had a return on equity of 14.29% and a net margin of 29.81%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.45 earnings per share. On average, analysts expect Anika Therapeutics to post $1.84 EPS for the current fiscal year and $1.69 EPS for the next fiscal year.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 46.47 on Tuesday. The stock’s 50 day moving average price is $47.03 and its 200-day moving average price is $47.10. Anika Therapeutics Inc. has a 1-year low of $41.38 and a 1-year high of $53.50. The company has a market capitalization of $680.97 million, a PE ratio of 22.43 and a beta of 1.68.
In related news, CEO Charles H. Sherwood sold 14,201 shares of the stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total transaction of $710,476.03. Following the sale, the chief executive officer now directly owns 246,740 shares of the company’s stock, valued at $12,344,402.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffery S. Thompson sold 10,725 shares of the stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $47.39, for a total value of $508,257.75. Following the sale, the director now directly owns 15,845 shares in the company, valued at $750,894.55. The disclosure for this sale can be found here. Company insiders own 6.57% of the company’s stock.
Separately, Zacks Investment Research raised Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
What are top analysts saying about Anika Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics Inc. and related companies.